Common use of Investor Review Clause in Contracts

Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.

Appears in 7 contracts

Samples: Registration Rights Agreement (Senti Biosciences, Inc.), Registration Rights Agreement (Aclaris Therapeutics, Inc.), Registration Rights Agreement (Neurogene Inc.)

AutoNDA by SimpleDocs

Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three four (34) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.

Appears in 3 contracts

Samples: Registration Rights Agreement (Biodesix Inc), Registration Rights Agreement (Pyxis Oncology, Inc.), Registration Rights Agreement (IO Biotech, Inc.)

Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investorsany Investor, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors Investor and their its counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due good faith consideration to any comments thereon received from the Investors Investor or their its counsel.

Appears in 2 contracts

Samples: Registration Rights Agreement (Aerovate Therapeutics, Inc.), Securities Purchase Agreement (Aerovate Therapeutics, Inc.)

Investor Review. The Company will not file any amendment or supplement to the Initial Registration Statement, Warrant Initial Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.

Appears in 1 contract

Samples: Registration Rights Agreement (Inhibikase Therapeutics, Inc.)

Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due good faith consideration to any comments thereon received from the Investors or their counsel.

Appears in 1 contract

Samples: Registration Rights Agreement (Cidara Therapeutics, Inc.)

AutoNDA by SimpleDocs

Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.

Appears in 1 contract

Samples: Registration Rights Agreement (Tenax Therapeutics, Inc.)

Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three one (31) Business Days Day prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.

Appears in 1 contract

Samples: Registration Rights Agreement (Summit Therapeutics Inc.)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!